8-K: MAIA Biotech Presents THIO-101 NSCLC Trial Data

MAIA Biotechnology, Inc. announced the presentation of Phase 2 data for its THIO-101 trial in advanced NSCLC at a major cancer conference.

Summary

• MAIA Biotechnology, Inc. (MAIA) filed a Form 8-K to announce the presentation of a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
• The poster, titled 'A Phase 2 Study of Ateganosine (THIO; 6-thio-2-deoxyguanosine) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Resistant to Prior ICI and Chemotherapy: THIO-101 Trial,' was presented on October 24, 2025, in Boston, Massachusetts.
• The poster was also made available on the company's website on the same date.
• The filing notes that the poster contains forward-looking statements, and investors should not place undue reliance on them.
• The specific content, data, and results from the poster (Exhibit 99.1) were not provided in this filing, therefore a detailed analysis of the trial's outcomes is not possible based solely on this document.

Sentiment

Score: 5

Explanation: The filing is neutral as it solely announces the presentation of clinical trial data without providing the actual results or any financial implications. The event itself is a standard operational update for a biotechnology company.

Positives

• The presentation of Phase 2 clinical trial data at a reputable international conference (AACR-NCI-EORTC) indicates progress in the development of Ateganosine (THIO) for advanced NSCLC.

Negatives

• The filing itself does not contain the specific data or results from the poster, preventing a detailed assessment of any potential negative outcomes or challenges in the THIO-101 trial.

Risks

• The poster contains forward-looking statements, which inherently carry risks and uncertainties, and investors are cautioned not to place undue reliance on them.

Future Outlook

The filing indicates that the poster contains forward-looking statements, but no specific guidance or future outlook details are provided within the 8-K itself.

Management Comments

• Vlad Vitoc, Chief Executive Officer, signed the report on behalf of MAIA Biotechnology, Inc.

Industry Context

Presenting clinical trial data at major scientific conferences like AACR-NCI-EORTC is a standard practice for biotechnology companies to disseminate research findings, engage with the scientific community, and update stakeholders on drug development progress. This event positions MAIA Biotechnology within the competitive oncology drug development landscape, particularly in the challenging area of advanced NSCLC resistant to existing therapies.

Stakeholder Impact

• Shareholders and potential investors will be interested in the full content of the poster to assess the progress and potential of Ateganosine in the THIO-101 trial for advanced NSCLC.

Key Dates

Keywords

MAIA Biotechnology, Ateganosine, THIO, THIO-101, NSCLC, Non-Small Cell Lung Cancer, Phase 2, Clinical Trial, Oncology, Cancer Therapeutics, Biotechnology, Immune Checkpoint Inhibitor, ICI